Adalimumab

Introduction Overview

Generic Name

adalimumab

Brand Name

Humira

Dosage Form

single-dose prefilled pen (80 mg/0.8 mL, 40 mg/0.8 mL, 40 mg/0.4 mL), single-dose prefilled glass syringe (80 mg/0.8 mL, 40 mg/0.8 mL, 40 mg/0.4 mL, 20 mg/0.4 mL, 20 mg/0.2 mL, 10 mg/0.2 mL, 10 mg/0.1 mL), single-dose glass vial (40 mg/0.8 mL)

Drug Class

Antirheumatics, TNF alpha inhibitors

Pharmacokinetics

Absorption: Adalimumab is administered subcutaneously with bioavailability approximating 64%. After subcutaneous injection, adalimumab reaches peak serum concentrations in about 4 to 7 days, demonstrating relatively slow absorption due to its monoclonal antibody nature, which limits passive diffusion through the capillary endothelium. Absorption can be influenced by factors such as injection site, method, and local blood flow. Distribution: The volume of distribution for adalimumab is limited to the vascular and interstitial spaces, consistent with its large molecular size (~148 kDa). It distributes primarily in extracellular fluid compartments with limited penetration into tissues or cells. It does not cross the blood-brain barrier or placenta in significant amounts but may be detected in trace concentrations in breast milk. Metabolism: As a monoclonal antibody, adalimumab undergoes proteolytic catabolism by ubiquitous proteases resulting in amino acid breakdown products. Unlike small molecules, it does not undergo hepatic metabolism via cytochrome P450 enzymes, minimizing potential metabolic drug-drug interactions. Its elimination is via normal protein catabolic pathways, rather than renal or hepatic excretion. Elimination: The elimination half-life of adalimumab averages approximately 2 weeks (10-20 days), supporting dosing intervals of every one to two weeks. Clearance occurs through target-mediated disposition and reticuloendothelial system proteolysis. Immunogenicity leading to anti-drug antibodies can alter pharmacokinetics by increasing clearance, reducing serum concentrations and clinical effectiveness. Because of its long half-life, steady-state concentrations are typically achieved by week 12 of therapy. Dose adjustments may be necessary in cases of altered clearance due to immunogenicity or severe inflammation.

Dosage Forms

Available Dosage Forms: Humira is provided as single-dose prefilled pens and prefilled glass syringes in various strengths: 80 mg/0.8 mL, 40 mg/0.8 mL, 40 mg/0.4 mL, 20 mg/0.4 mL, 20 mg/0.2 mL, 10 mg/0.2 mL, 10 mg/0.1 mL. Additionally, it is available as a single-dose glass vial of 40 mg/0.8 mL for institutional use. Specific formulations contain varying excipients including citric acid monohydrate, sodium phosphate dihydrates, mannitol, polysorbate 80, sodium chloride, sodium citrate, and Water for Injection. Dosage pens and syringes vary in latex content in needle covers, important for patients with latex allergy. Dosages for Adults and Adolescents: Dosing varies by indication. For rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, adults typically receive 40 mg subcutaneously every other week, with potential adjustment to weekly dosing or 80 mg every other week in certain cases. For Crohn’s disease and ulcerative colitis, initial induction doses are 160 mg subcutaneously at Day 1 (single dose or split over two days), followed by 80 mg at Day 15, and maintenance dosing of 40 mg every other week starting Day 29. Plaque psoriasis and uveitis treatment involve an initial 80 mg dose followed by 40 mg every other week starting one week later. For hidradenitis suppurativa, an initial 160 mg dose (day 1 or split), 80 mg at day 15, then maintenance of 40 mg weekly or 80 mg every other week beyond day 29. Pediatric dosing is indicated for juvenile idiopathic arthritis (≥2 years), Crohn’s disease (≥6 years), ulcerative colitis (≥5 years), and uveitis (≥2 years), with regimens adapted based on body weight and clinical response. Specific Patient Populations: Pediatric patients receive weight-based dosing tailored to disease severity. Immunocompromised individuals require vigilance for infections. Due to lack of formal pharmacokinetic studies in hepatic or renal impairment, no specific dosing adjustments are recommended, but caution is advised. Pregnant patients should be assessed for benefit-risk ratio; adalimumab crosses the placenta and may affect neonatal immune function. Elderly patients generally tolerate standard dosing but require monitoring for infections and malignancies. Patients with latex allergy should avoid formulations containing latex in needle covers.

Mechanism Of Action

Humira (adalimumab) is a fully human recombinant monoclonal antibody of the IgG1 subclass engineered to specifically bind to tumor necrosis factor-alpha (TNF-α), a proinflammatory cytokine critically involved in autoimmune and inflammatory processes. By binding with high affinity and specificity to soluble and membrane-bound TNF-α, adalimumab neutralizes its biological activity, preventing TNF-α from interacting with its cell surface receptors TNFR1 and TNFR2. This blockade inhibits TNF-α-induced signaling pathways that promote expression of inflammatory mediators, adhesion molecules, and chemokines, thereby mitigating endothelial activation, leukocyte recruitment, and tissue damage. At the cellular level, adalimumab also induces apoptosis of TNF-expressing cells and reduces infiltration of inflammatory cells into affected tissues. Biochemically, the suppression of TNF-α activity decreases the downstream activation of nuclear factor-kappa B (NF-κB) and other transcription factors responsible for perpetuating chronic inflammation. Clinically, this leads to reduced joint inflammation and destruction in rheumatoid arthritis, decreased plaque formation in psoriasis, and attenuated intestinal inflammation in Crohn’s disease and ulcerative colitis. When compared to other TNF inhibitors, such as infliximab (a chimeric antibody) and etanercept (a TNF receptor fusion protein), adalimumab’s fully human antibody structure reduces immunogenicity risks and allows for subcutaneous administration, enhancing patient compliance. Clinical trials have demonstrated its efficacy across a spectrum of autoimmune diseases, with durable suppression of inflammatory pathways. Ongoing research explores its potential immunomodulatory effects on other cytokines and immune cell subsets, underscoring its versatile role in managing complex immune-mediated disorders.

Pharmacological Actions

Selective inhibition of tumor necrosis factor-alpha (TNF-α), a central cytokine in inflammatory and immune responses.
Neutralization of both soluble and transmembrane TNF-α forms, preventing receptor binding and activation.
Downregulation of pro-inflammatory cytokines and chemokines induced downstream of TNF-α signaling.
Reduction of inflammatory cell infiltration through inhibition of leukocyte adhesion and migration.
Induction of apoptosis in activated T lymphocytes and macrophages expressing TNF-α.
Suppression of endothelial activation and vascular inflammation.
Modulation of immune system pathways implicated in autoimmune disease pathogenesis.
Exertion of anti-inflammatory and immunosuppressive effects beneficial in autoimmune and chronic inflammatory diseases.
Improvement of clinical symptoms in rheumatoid arthritis, psoriasis, Crohn’s disease, ulcerative colitis, and other indications.
Potential amelioration of structural joint damage by inhibiting cartilage and bone destruction mediated by inflammation.
Reduction of systemic inflammatory markers such as C-reactive protein (CRP).
Alteration of T cell subsets and regulatory mechanisms contributing to immune homeostasis.
Demonstration of dose-dependent pharmacodynamic effects correlating with clinical response.
Potential limitation of fibrotic processes through TNF-α suppression.
Interactions with Fc receptors that may influence antibody-dependent cellular cytotoxicity (ADCC).

Therapeutic Or Clinical Uses

Treatment of moderate to severe rheumatoid arthritis (RA) in adults, either as monotherapy or in combination with methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
Management of moderate to severe polyarticular juvenile idiopathic arthritis (JIA) in children aged 2 years and older.
Therapy for psoriatic arthritis (PsA) in adult patients, for improvement of joint symptoms and prevention of structural damage.
Treatment of ankylosing spondylitis (AS) in adults to reduce symptoms and improve physical function.
Management of moderate to severe hidradenitis suppurativa (HS) in patients aged 12 years and older.
Induction and maintenance of remission in moderate to severe Crohn’s disease (CD) in adults and pediatric patients aged 6 years and above.
Induction and maintenance treatment of moderate to severe ulcerative colitis (UC) in adult and pediatric patients aged 5 years and above.
Treatment of moderate to severe chronic plaque psoriasis in adults, especially for patients requiring systemic therapy or phototherapy.
Management of non-infectious intermediate, posterior, and panuveitis in adult and pediatric patients aged 2 years and older.
Use as a biologic agent targeting TNF-α-mediated inflammatory pathways across various immune-mediated disorders.
Therapeutic option for patients intolerant or unresponsive to conventional therapies.
Combination therapy with immunosuppressants, corticosteroids, or NSAIDs as clinically indicated.
Reduction of disease activity scores and patient-reported symptom improvements in clinical trials.
Use in managing extra-articular manifestations associated with autoimmune diseases.
Treatment compliance enhanced by subcutaneous administration and self-injection devices.

Side Or Adverse Effects

Injection site reactions including redness, swelling, rash, itching, bruising, and pain occurring commonly but usually resolving within days.
Upper respiratory tract infections such as sinusitis and nasopharyngitis.
Headaches of varying severity reported across patient populations.
Skin rash and other dermatological reactions including new onset or exacerbation of psoriasis.
Serious infections including tuberculosis, bacterial, viral, fungal, and other opportunistic infections due to immune suppression.
Rare cases of lymphoma and other malignancies including hepatosplenic T-cell lymphoma, especially in younger patients or those on concomitant immunosuppressants.
Reactivation of latent hepatitis B virus infection with associated liver damage.
Allergic reactions ranging from mild hypersensitivity to anaphylaxis manifesting as hives, facial swelling, and difficulty breathing.
Neurological disorders including demyelinating conditions, numbness, tingling, dizziness, and vision changes.
Hematological abnormalities such as pancytopenia, neutropenia, and thrombocytopenia.
New onset or worsening heart failure symptoms including dyspnea, swelling, and sudden weight gain.
Autoimmune phenomena such as lupus-like syndrome presenting with chest pain, rash, and joint discomfort.
Elevated liver enzymes and liver dysfunction potentially progressing to liver failure.
Risk of injection site abscesses or cellulitis requiring medical intervention.
Potential for immunogenicity leading to decreased efficacy or hypersensitivity.

Precautions

Screen patients for latent tuberculosis prior to initiating Humira therapy and monitor closely during treatment.
Evaluate for hepatitis B virus carrier status before starting therapy and monitor for reactivation throughout treatment and after discontinuation.
Avoid use in patients with active infections or sepsis; delay therapy until infection is fully treated.
Use cautiously in patients with a history of recurrent infections or immunocompromised states.
Monitor for signs and symptoms of malignancies, including lymphoma and skin cancers.
Exercise caution in patients with preexisting demyelinating neurological disorders or heart failure.
Assess for potential hypersensitivity or allergic reactions, and discontinue if severe reactions occur.
Ensure patients receiving live vaccines are appropriately timed and avoid live vaccines during therapy.
Advise patients to avoid exposure to individuals with infections considering immunosuppressive effects.
Maintain vigilance for autoimmune phenomena such as lupus-like syndrome and discontinue if symptoms develop.
Consider latex allergy status due to presence of natural rubber in some formulations’ needle covers.
Pregnant patients should be counseled regarding potential fetal risks and newborn immune function monitoring.
Use in pediatric populations should be guided by specialist with attention to immunization status.
Patients scheduled for major surgery require thorough risk-benefit assessment and monitoring for infections.
Educate patients on proper injection techniques, storage conditions, and disposal of sharps to prevent injury.

Warnings

Black box warning for increased risk of serious infections including tuberculosis, sepsis, and opportunistic infections which can be fatal.
Potential increased risk of malignancies, including lymphoma and hepatosplenic T-cell lymphoma, particularly in pediatric and young adult Crohn’s disease and ulcerative colitis patients.
Monitor closely for symptoms indicative of new or worsening infections such as persistent cough, fever, weight loss, or fatigue.
Risk of reactivation of latent hepatitis B virus infection leading to hepatic failure.
Risk of serious allergic and anaphylactic reactions requiring immediate emergency intervention.
Possible development or exacerbation of demyelinating diseases including multiple sclerosis symptoms.
New or worsening congestive heart failure symptoms warrant discontinuation and evaluation.
Use with caution when combined with other immunosuppressants due to additive risk of infection and malignancy.
Discontinue therapy if lupus-like syndrome or other severe autoimmune disorders develop.
Avoid live vaccines during and after Humira treatment until immune competence is restored.
Potential for immunogenicity leading to loss of efficacy or hypersensitivity reactions.
Latex allergy warning for certain product presentations containing natural rubber latex in needle covers.
Carefully consider risks before initiating therapy in elderly patients who may have higher risk of adverse events.
Pregnancy and breastfeeding considerations regarding unknown safety profile and potential immunosuppressive effects on neonates.
Storage warnings to avoid freezing and maintaining refrigeration to preserve drug efficacy.

Contraindication

Known hypersensitivity or allergy to adalimumab, Humira, any of the biosimilars, or any of the inactive ingredients in the formulation.
Active serious infections including tuberculosis, sepsis, or opportunistic infections.
Concurrent use with other biologic TNF inhibitors (etanercept, infliximab) or certain immunosuppressants (abatacept, anakinra) due to increased risk of serious infections.
Patients with untreated or acute hepatitis B virus infection.
Patients with demyelinating diseases such as multiple sclerosis or Guillain-Barré syndrome should generally avoid use.
History of severe allergic or anaphylactic reaction to monoclonal antibodies.
Patients with moderate to severe heart failure unless benefits outweigh risks; contraindicated in worsening CHF.
Use in patients with latex allergy for specific formulations containing latex in needle covers without alternative products.
Known hypersensitivity reactions to formulations containing polysorbate 80 or other excipients.
Concurrent administration with live vaccines due to risk of vaccine-associated disease.
Patients with active malignancies unless benefits clearly justify treatment.
Contraindicated in patients who have experienced severe infusion-related or injection site reactions to prior dosing.
Use caution or avoid in populations with compromised immune systems without specialist consultation.
Discontinuation advised if severe hematological abnormalities develop during treatment.
Discontinue if serious hypersensitivity or systemic allergic reactions occur.

Drug Interactions

Concomitant use with other TNF inhibitors (etanercept, infliximab, certolizumab, golimumab) increases risk of serious infections and is not recommended.
Combination with immunosuppressants like azathioprine and 6-mercaptopurine may increase immunosuppression and infection risk but is sometimes clinically indicated under monitoring.
Co-administration with rituximab or abatacept increases risk of immunosuppression and infections; caution advised.
Use with anakinra may elevate risk of neutropenia, infections, and should generally be avoided.
No significant interactions with cytochrome P450 substrates as adalimumab is protein-based and not metabolized by CYP enzymes.
Live vaccines are contraindicated during and after Humira therapy until immune system recovery.
Concomitant use with corticosteroids and NSAIDs is common but requires careful infection monitoring.
Potential interference with immunogenic response to vaccinations; non-live vaccines are preferred.
Minimal pharmacokinetic drug-drug interactions due to monoclonal antibody nature but pharmacodynamic interactions possible.
Possible reduction in Humira efficacy due to formation of anti-drug antibodies influenced by concomitant medications.
Monitoring advised when combined with drugs affecting immune function or bone marrow activity.
No significant interactions with common over-the-counter medications or herbal supplements documented but clinical vigilance warranted.
Interactions with blood glucose-lowering agents or other comorbidity treatments are rare but monitoring recommended.
Drug interaction profile influenced by patient-specific factors including underlying diseases and concurrent medications.
Patient counseling should include disclosure of all medications to healthcare provider to evaluate potential interactions.

Preparations Of The Drug

Humira Pen: single-dose prefilled pen available in 80 mg/0.8 mL, 40 mg/0.8 mL, and 40 mg/0.4 mL strengths; latex content varies by strength.
Humira Prefilled Syringe: single-dose glass syringe in multiple strengths including 80 mg/0.8 mL, 40 mg/0.8 mL, 40 mg/0.4 mL, 20 mg/0.4 mL, 20 mg/0.2 mL, 10 mg/0.2 mL, and 10 mg/0.1 mL; some formulations contain latex in needle cover.
Humira Single-Dose Vial: 40 mg/0.8 mL for institutional use; latex free stopper.
Biosimilar and Interchangeable Products: Includes Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Simlandi, and Yuflyma among others, available in various autoinjector, prefilled syringe, and single-dose vial forms matching Humira strengths.
Packaging includes carton with storage instructions recommending refrigeration between 2°C and 8°C; do not freeze.
Patient instruction leaflets provided for self-injection and proper handling techniques.
Single-use syringes and pens designed for subcutaneous administration; disposal following puncture-proof protocols.
Formulations incorporate excipients such as mannitol, polysorbate 80, citric acid monohydrate, sodium chloride, and buffers to enhance stability.
Latex-free options available for patients with latex sensitivity in selected products.
Product storage recommendations include protection from light and temperature excursions during transport and handling.
Instruction for use includes guidance on inspecting drug appearance before administration to ensure clarity and lack of particulate matter.
Patient assistance and educational materials offered to support adherence and correct self-injection practices.
Humira is marketed and manufactured by AbbVie Inc., with regulatory approvals from FDA and worldwide authorities.
Ongoing development and approval of additional biosimilars provide therapeutic alternatives with comparable efficacy and safety.